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Platelets play a central role in ischemic cardiovascular events. Cardiovascular disease (CVD) is a major cause of death worldwide.
Numerous genome-wide association studies (GWASs) have identified loci associated with CVD risk. However, our understanding of
how these variants contribute to disease is limited. Using data from the platelet RNA and expression 1 (PRAX1) study, we analyzed
cis expression quantitative trait loci (eQTLs) in platelets from 154 normal human subjects. We confirmed these results in silico by per-
forming allele-specific expression (ASE) analysis, which demonstrated that the allelic directionality of eQTLs and ASE patterns correlate
significantly. Comparison of platelet eQTLs with data from the Genotype-Tissue Expression (GTEx) project revealed that a number of
platelet eQTLs are platelet specific and that platelet eQTL peaks localize to the gene body at a higher rate than eQTLs from other tissues.
Upon integration with data from previously published GWASs, we found that the trait-associated variant rs1474868 coincides with the
eQTL peak for mitofusin 2 (MFN2). Additional experimental and computational analyses revealed that this eQTL is linked to an unan-
notated alternateMFN2 start site preferentially expressed in platelets. Integration of phenotype data from the PRAX1 study showed that
MFN2 expression levels were significantly associated with platelet count. This study links the variant rs1474868 to a platelet-specific reg-
ulatory role for MFN2 and demonstrates the utility of integrating multi-omic data with eQTL analysis in disease-relevant tissues for in-
terpreting GWAS results.Introduction
Cardiovascular disease (CVD) is a major cause of death
worldwide. Thrombotic events, such as myocardial infarc-
tion (MI) and stroke, occur when occlusive platelet
thrombi form at the site of a ruptured atherosclerotic pla-
que.1–5 The critical role of platelets in the pathophysiology
of CVD events is further underscored by the standard use
of anti-platelet agents in the management of the disease.
However, there is little mechanistic understanding to
explain why some individuals form occlusive thrombi at
the site of ruptured atherosclerotic plaques, whereas other
individuals repair the wound without occluding the vessel.
Inter-individual variation in platelet reactivity,6 volume,
and number7 are likely contributors given that these
platelet phenotypes have been prospectively shown to be
a risk for recurrent coronary syndromes.8 Abundant evi-
dence suggests that CVD has a genetic component.9–13
However, the genetic mechanisms underlying CVD risk
in the general population are not fully characterized.
Genome-wide associations studies (GWASs) have identi-
fied links between CVD risk and genetic variants. However,
many disease-associated variants are located in non-coding
regions of the genome, making it difficult to identify the
mechanism of function.14–16 Moreover, variations at the
DNA level do not pinpoint a tissue of action critical to
the development of a higher-level GWAS phenotype such
as CVD.17 Integration of expression quantitative trait loci
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these challenges.18 eQTLs can provide mechanistic in-
sights into gene expression in disease-relevant tissues by
identifying cell-type-specific regulatory variants. There-
fore, eQTL data are considered a key intermediate to con-
necting expression changes with higher-level phenotypes
and clinical outcomes represented by GWAS results.19,20
Given the role platelets play in the etiology and patho-
genesis of CVD, we hypothesized that eQTL analysis in
human platelets might connect regulatory variants in
platelets with functional expression changes at loci previ-
ously linked to CVD by GWASs. Although platelets lack a
nucleus, they inherit their transcriptome from their parent
bonemarrow progenitors, megakaryocytes. Because it is far
easier to obtain platelets and because their transcriptome
strongly correlates with that of megakaryocytes,21,22
platelet RNA represents a valuable resource for identifying
and characterizing relevant gene expression in thrombotic
disorders. We now report a generalizable approach for link-
ing GWAS hits to physiology and disease. This approach
integrates cell-type-specific eQTL analysis with primary-
tissue multi-omic data from the platelet RNA and expres-
sion 1 (PRAX1) study together with other public datasets,
such as those of the Genotype-Tissue Expression (GTEx)
project23 and ENCODE.24 Our analyses and experiments
with rs1474868, previously associated with MI by
GWASs,25 revealed that rs1474868 marks the platelet
MFN2 (MIM: 608507) eQTL peak and drives expression
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addition, we identified a significant association between
MFN2 expression levels and platelet count. Overall, our
findings demonstrate the power of integrating primary-tis-
sue eQTL analysis with multi-omic data to interpret and
inform functional genomics of GWASs in CVD and other
diseases.Material and Methods
The PRAX1 Study
The goal of the PRAX1 study was to identify gene-expression
correlates responsible for inter-individual variation in platelet
function. As described earlier,26,27 154 healthy individuals (80 of
European and 74 of African ancestry) were recruited between
2010 and 2011. For all individuals, demographic information
was collected, and platelet functional phenotyping, genome-
wide genotyping, and global mRNA profiling were performed.
We obtained a complete blood count and mean platelet volume
by using an ABX Micros 60 CS (Horiba ABX). Informed consent
was obtained from all participants with the approval of the insti-
tutional review boards of Baylor College of Medicine in Houston
and Thomas Jefferson University in Philadelphia. Research was
conducted in accordance with the Declaration of Helsinki.
Gene Expression Data from the PRAX1 Study
We measured gene expression of PRAX1 samples by using the
Human Gene 1.0 ST microarray (Affymetrix) as described previ-
ously28 (these data are available in the Gene Expression Omnibus
under accession number GEO: GSE49921). eQTL mapping anal-
ysis was restricted to 5,695 autosomal, uniquely mapping,
commonly expressed platelet mRNAs as defined in Table S1 of
Simon et al.28
RNA-Seq Data from the PRAX1 Study
A subset of ten subjects from the PRAX1 study were analyzed with
RNA-sequencing (RNA-seq) technology in an independent study
by Londin et al.29 (The corresponding next-generation sequencing
data files are available in the Sequence Read Archive under study
identifier SRA: SRP028846.)Next,weconverted raw sequencingfiles
from SOLiD to FASTQ format and trimmed adapters with the ‘‘cuta-
dapt’’ tool. To improvemapping accuracy, we performed a two-pass
alignment strategy as outlined in Engstrom et al.30 First, we used
STARv.2.3.1 to align reads to theUCSCGenomeBrowser hg19 refer-
ence genome.We then used the resulting file on splice junction loci
and the hg19 FASTA sequence to generate sample-specific genomes
with the –genomeGenerate and –sjdbFileChrStartEnd functions.
Reads were subsequently aligned to each sample-specific hg19
index. As mentioned, these RNA-seq data have been previously
published, and no global quantification of gene expressionwas per-
formed for this current study, given that the RNA-seq data were
exclusively used in the allelic-imbalance analysis and detailed
follow-up analyses of MFN2 transcription. The RNA-seq data were
not used in the eQTL-mapping analysis.
Genotype Data from the PRAX1 Study
DNA from the buffy coats of PRAX1 study subjects was hybridized
to the HumanOmni5 array (Illumina) as described earlier26 and
genotyped for approximately five million markers. Genotype
data were restricted to 1,927,172 markers passing a cohort-specific
minor-allele-frequency cutoff of 5%.884 The American Journal of Human Genetics 98, 883–897, May 5, 2eQTL Mapping
We applied a two-pass eQTL-mapping strategy. First, we used
cohort genotype- andmicroarray-based expression data to identify
612 genes containing at least one significant eQTL association (p<
1e6, multiple linear regression), termed eGenes. Next, using
IMPUTE2 and data from the 1000 Genomes Project, we imputed
additional genotypes only for those 612 eGenes. Finally, we
repeated association testing by using the extended set of both gen-
otyped (368,794) and imputed (1,071,757) variants to fine map
the platelet eQTL landscape of these 612 eGenes. We used R statis-
tical software v.3.0.1 in conjunction with the MatrixEQTL pack-
age31 to determine significant associations between variant-allele
dosage and gene expression levels. We restricted the cis search
space to within 500 kb of the transcription start site and used
variant-allele dosage (0, 1, and 2) to additively model associations.
The following parameters were used: useModel ¼ modelLINEAR,
pvOutputThreshold.cis ¼ 1e6, and cisDist ¼ 5e5. To account
for hidden trans covariates, we used the probabilistic estimation
of expression residuals (PEER) framework32 and inferred 15 PEER
factors. These PEER factors capture trans variation, such as batch
effects or global ethnic differences, present in the gene expression
data. Accounting for these trans factors when modeling cis eQTLs
improves the power to detect true cis eQTLs by reducing spurious
false-positive associations.32 Therefore, we included these 15 PEER
factors—in addition to age, gender, and the first two genotype
principal components, which completely account for self-identi-
fied ethnicity26—as covariates in the model. The same settings
were used during the first (genotyped variants) and second (geno-
typed and imputed variants) passes of the eQTL mapping. Signif-
icant eQTLs were defined as variants associated with expression
levels of genes at a p value threshold of 1e6 to account for mul-
tiple testing. eGenes were defined as genes associated with at least
one significant eQTL.Imputation
To obtain amore granular view of the eQTL landscape, we imputed
additional genotypes across the cis search space of each eGeneprior
to the second pass of the eQTLmapping.We used IMPUTE2 v.2.3.2
software33 and the 1000 Genomes phase 1 integrated variant-set
release as a reference to infer additional genotypes. The imputation
software first phases the study genotypes and subsequently im-
putes additional genotypes by integrating study-subject phasing
informationwithknownhaplotypes fromthe1000Genomes refer-
ence data. We followed the instructions provided on the IMPUTE2
website. In short, original genotypeswere extracted for each eGene
spanning the 1 Mb cis search space. Genotypes were pre-phased
with the –prephase_g function. We downloaded prephased 1000
Genomes phase 1 integrated haplotypes. Using these pre-phased
haplotypes as a reference, we imputed samples from the PRAX1
study with the –use_prephased_g function, for which haplotype
and legend files for all 1,092 1000 Genomes samples (246 AFR [Af-
rican], 181AMR [admixedAmerican], 286EAS [EastAsian], and379
EUR [European]) and the PRAX1 study genotype were provided
with the –h, –l, and –g parameters, respectively. Imputed genotypes
called with high confidence (maximum probability > 0.9) were
used in subsequent analysis. Accuracy analysis was performed
with the IMPUTE2 internal cross-validation system. During each
run, IMPUTE2 masks a subset of observed variants and subse-
quently imputes these genotype data by using flanking markers.
The imputation accuracy can be quantified as the percentage of
concordance between known and imputed genotypes of these016
cross-validated variants. In the cross-validation analyses, the
percentage of concordance across the 612 eGene regions was very
high (minimum ¼ 96.4%, median ¼ 98.7%, maximum ¼ 99.7%),
indicating accurate imputation results. Because of the nature of
overlapping cis search spaces, somevariantswere imputedmultiple
times. In these cases, imputed genotypes with discordant results
were excluded.Conditional eQTL Analysis
To investigate how many independent eQTL signals contribute to
the regulation of a single eGene, we performed conditional eQTL
analysis. This analysis followed the procedures outlined in the
eQTL Mapping section, but additionally, the genotype of the
marker for the corresponding eQTL peak was added as a covariate
for each of the 612 eGenes. If no variants remained significantly
associated with expression of the corresponding eGene (p <
1e6) after we accounted for the genotype of the marker at the
eQTL peak, we defined the given eGene as regulated by a single ge-
netic signal. If a significant association remained, we interpreted it
as evidence of a second independent genetic signal.Analysis of Allele-Specific Expression
We analyzed allele-specific expression (ASE) with our ten RNA-seq
samples from the PRAX1 study. Using the reference genome to
map RNA-seq data can be biased by genetic variation, given that
reads carrying the non-reference allele are less likely to map
correctly.34 This mapping bias is called reference-allele bias and is
a non-trivial confounding variable in ASE analysis.35 To overcome
this challenge, we aligned RNA-seq reads to inferred personalized
genomes on the basis of the genotype data observed in the study.
This specialized alignment was used in the ASE analysis only. To
generate personalized genomes corresponding to the ten RNA-seq
samples from thePRAX1 study,weused IMPUTE2v.2.3.2 to impute
genotypes across 22 autosomal chromosomes (as outlined in the
Imputation section); this procedure generates a high-density map
of the personal variation present in each sample. Following the rec-
ommendations on the IMPUTE2website regarding the imputation
of entire chromosomes, we divided each chromosome into 500 kb
intervals and imputed each interval separately. Phasing informa-
tion obtained from the imputation can be used for inferring
parental haplotypes across genetic regions, such as genes. We
used the ‘‘vcf2diplod’’ function provided in the AlleleSeq36 soft-
ware to generate two paternal-genome FASTA files for each sample.
Next, we used the –genomeGenerate parameter of STAR v.2.3.1 to
generate two separate parental-genome indices for each sample.
Because of imputed insertion and deletions, the ‘‘liftOver’’37 func-
tion was needed to convert genomic coordinates between ge-
nomes. Next, for each sample, we used STAR v.2.3.1 to align the
corresponding FASTQ read file to the two paternal genomes inde-
pendently. Figure S1 shows that reference-allele bias decreased
when RNA-seq reads were aligned to personalized genomes rather
than thehg19 reference genome.Next, readpileupswere generated
with an adapted version of the pipeline outlined in Harvey et al.38
In short, SAMtools39 was used to generate read pileups at 128,163
(genotyped and imputed) sites, which were used in the eQTL-map-
ping analysis and fell into coding regions according to the UCSC
Genome Browser hg19 knownGene table downloaded in January
2015. Next, heterozygous sites within each of the ten PRAX1 study
samples were identified and assessed for coverage. Heterozygous
coding sites with ten or more reads in a sample were required for
the site to be considered in the ASE analysis. To ensure that map-The Ampingbias didnot affect the calculations,we calculated and recorded
the pair of counts for each parental allele from the alignment to the
corresponding personalized parental genome. Because a gene can
harbor more than one heterozygous coding site in a given sample,
we picked the pileup site with the lowest eQTL association p value
to examine allelic imbalance. Allelic imbalance was defined as an
unequal count of two alleles at a given heterozygous pileup site
in a sample. To evaluate the global correspondence between allelic
imbalance and the genome-wide global eQTL findings, we used
Fisher’s exact test. The null hypothesis states that the directionality
of allelic imbalance is independent of the allelic directionality of
the eQTL. In other words, the likelihood of observing a higher frac-
tion of the reference allele than of the alternative allele at a given
pileup site is independent of the allele implicated with higher
expression levels in the eQTL analysis. Directional deviation from
this null hypothesis would indicate concordance between allelic
imbalances and eQTLs. For the exemplary eGeneCXCL5, we devel-
oped a separate statistical approach. In order to give equalweight to
each sample, we downsampled allelic counts of each heterozygous
sample to the minimum sum of allelic counts among all heterozy-
gous samples.Next,we summed these counts into anaggregatepair
of counts and performed a binomial test. The null hypothesis for
this test states that the likelihoods of observing the reference and
alternative alleles are equal, so that reads are generated as coin-flip-
ping trials of a fair coin. Appropriate deviation from this null hy-
pothesis can indicate that allelic imbalance corresponds to the
allelic directionality of the eQTL; p values were determined for a
one-sided binomial test.GTEx Data
These data consist of a resource database and associated tissue
bank for studying the relationship between genetic variation
and gene expression in human tissues. We downloaded the
GTEx_Analysis_V6_eQTLs.tar.gz table, containing significant sin-
gle-tissue variant-gene associations from the GTEx website. These
data catalog eQTLs across 46 different tissues. To increase compa-
rability, we restricted analysis to 20 GTEx tissues with a sample size
equal to or higher than our PRAX1 study cohort (154) and rede-
fined all GTEx eGenes according to our definition: GTEx eGenes
for each tissue were defined as genes containing at least one signif-
icant eQTL (p< 1e6) within 500 kb of the transcription start site.
Our definition of an eGene was more stringent than the rules
applied by GTEx. Across the 20 tissues analyzed, on average, a sub-
set of 71% of GTEx eGenes remained an eGene according to our
definition. An eQTL peak was defined as the genomic location of
the most strongly associated eQTL variant(s) within each eGene.
Table S3 lists eQTL peaks for GTEx and platelet eGenes. To account
for varying sample sizes inherent in the GTEx eQTL dataset, we
used Jaccard similarity to compare overlap between platelet and
GTEx eGenes. To perform a more granular comparison, we con-
ducted an additional analysis at the variant-gene association level.
For each eGene we identified the strongest platelet eQTL associa-
tion present in each of the GTEx tissues. Next, we compared the
sign of the allelic effect of the eQTL association. Concordance be-
tween the sign of the allelic effects of eQTL associations in plate-
lets and each GTEx tissue was calculated with Fisher’s exact test.
The null hypothesis is that the sign of the allelic effect of the
eQTL in platelets is independent of the sign of the allelic effect
in the tissue of comparison. Directional deviation from this hy-
pothesis can indicate concordance of allelic effects between the
tissues at the variant-gene level.erican Journal of Human Genetics 98, 883–897, May 5, 2016 885
CVD GWAS Associations
We used the Phenotype-Genotype Integrator25 to download previ-
ously published GWAS results. We restricted analyses to variants
associated with traits annotated to the Medical Subject Headings
(MeSH) category ‘‘cardiovascular diseases’’ and an association
p value below 1e4. These data catalog variant-phenotype associ-
ations and were integrated with the variant-eGene associations
identified in our eQTL analysis.
Additional Platelet RNA-Seq Data
We downloaded additional platelet RNA-seq data from three previ-
ous studies by Rowley et al.,40 Kissopoulou et al.,41 and Eicher
et al.42 For the Rowley et al. data, RNA-seq alignments were down-
loaded according to the instructions outlined in Rowley et al.40 For
the Kissopoulou et al. data,41 next-generation sequencing FASTQ
files were downloaded from the ArrayExpress website under
accession number E-MTAB-1846. Reads were aligned to the hg19
reference genome with STAR v.2.3.1 using default parameters.
For the Eicher et al. data,42 next-generation sequencing FASTQ
files and corresponding metadata were downloaded from
study SRP053296 in the Sequence Read Archive. Sample runs
SRR1792698 and SRR1792703 contained errors in the read-pairing
annotation and were excluded from further analysis. Reads were
aligned to the hg19 reference genome with STAR v.2.3.1 using
default parameters. These data comprise RNA-seq data from
different library-preparation protocols (total RNA, polyA, and
rRNA depleted) and sequencing technologies (Illumina and
SOLiD). Using data produced by different groups via different
techniques and protocols to validate RNA-seq-based findings
limits the chance of false-positive associations due to technical ar-
tifacts of the sequencing pipeline. Therefore, we used these inde-
pendent observations as evidence supporting the expression of
exon 2b in platelet MFN2 and an increase in sample size for asso-
ciative analyses.
In Silico Cross-Tissue Analysis
The Epigenome Roadmap project contains mRNA-seq data from
stem cells and primary ex vivo tissues selected to represent the
normal counterparts of tissues and organ systems frequently
involved in human disease. We used the Genboree Workbench43
to analyze mRNA-seq expression data for the MFN2 region from
69 samples. As input, we provided a customized bed file of 10 bp
intervals spanning theMFN2 region. Using this file, we calculated
average read density per interval for each sample. Replicates
within a sample type were averaged. Read-density averages across
these intervals for all samples can be found in Table S4.
PCR Confirmation of MFN2 Exon 2b
Leukocyte-depleted platelet RNA (henceforth referred to as
‘‘platelet RNA’’) was obtained via density centrifugation and im-
mune depletion of CD45þ cells as described previously.44 500 ng
of platelet RNA and SuperScript III (ThermoFisher Scientific)
were used for cDNA generation. PCR was performed to amplify
and detect the presence of the canonical MFN2 sequence
(GenBank: NM_014874.3) spanning exons 1–3 (primers F1 and
R1), the plateletMFN2 sequence spanning exons 2b and 3 (primers
F2 and R2), and exons 7–10 in ITG2B as a positive control for RNA
quality (primers ITG2B-F and ITG2B-R). The primer sequences
were as follows: 50-GGTGACGTAGTGAGTGTGATG-30 (F1), 50-CA
CTTAAGCACTTTGTCACTGC-30 (R1), 50-CCCAGCTGACCTGTT
TATTTG-30 (F2), 50-CTACATCCAGGAGAGCGC-30 (R2), 50-AGA886 The American Journal of Human Genetics 98, 883–897, May 5, 2GTACTTCGACGGCTACTG-30 (ITG2B-F), 50-GCAGCCTCTGGTAG
TAGGAA-30 (ITG2B-R).
50 Rapid Amplification of cDNA Ends of MFN2
To map the definitive 50 end of the platelet MFN2 transcript, we
used the SMARTer RACE (50 rapid amplification of cDNA ends)
50/30 Kit (Clontech) as described by the manufacturer. In brief,
1 mg platelet RNA was used for synthesis of first-strand cDNA,
which added a universal priming sequence to the 50 end of the first
strand via template switching. The 50 end of the cDNA was then
amplified in two rounds of nested PCR using primers that anneal
to the universal priming sequence (provided by the manufacturer)
and two gene-specific primers: 50-CACTTAAGCACTTTGTCA
CTGC-30 (GSP-1) and 50-CGGGTAGAGGGCACAGATGGCCAT
GAGG-30 (GSP-2). The products of the second round of amplifica-
tion were run on an agarose gel cloned into the pRACE vector with
the provided In-Fusion HD Cloning Kit. The cloned products were
then sequenced.
Relative Abundance of MFN2 Isoforms
The relative abundance ofMFN2 isoforms was calculated with the
splice-loci output generated from the STAR alignments for the
RNA-seq data from the PRAX1 study, Kissopoulou et al., and Eicher
et al. To estimate the relative abundance of theMFN2 isoform con-
taining exon 2b, we calculated the number of spliced reads that
mapped from the 30 border of exon 2b (chr1: 12,044,353, hg19)
to the 50 border of exon 3 (chr1: 12,049,221, hg19) and divided
it by the number of all spliced reads ending at the 50 border of
exon 3. Samples with ten or fewer junction reads ending at the
50 border of exon 3 were excluded.
Inference of rs1474868 Genotype
Because the variant rs1474868 falls into a coding region, we were
able to infer the rs1474868 genotype by using the STAR align-
ments for the Kissopoulou et al.41 and Eicher et al.42 data. Samples
withmore than one read containing the C or Tallele were assigned
the corresponding genotype. Samples with a total of fewer than
two reads were assigned the unknown status.
Transcription Factor Binding Sites
ENCODE chromatin immunoprecipitation followed by
sequencing (ChIP-seq) data on transcription factor binding were
downloaded from UCSC Genome Browser. We subsequently
restricted all data to experiments carried out in the hematopoiet-
ic-derived K562 cells.
MFN2 Luciferase Assays
DNA from two PRAX1 study subjects homozygous for C or T at
SNP rs3766744 was used as a template for amplifying two regions
surrounding this SNP: (1) a 655 bp region (chr1: 12,043,332–
12,043,986, hg19) was amplified with primers 50-GTTAGCC
AGGATGGTCTCGAAC-30 and 50-AACTTGCAAGCTGAGATTC
CAC-30, and (2) a 1,928 bp region (chr1: 12,042,341–12,044,268,
hg19) was amplified with primers 50-TTCGCTGGTTGCTTAGA
GAG-30 and 50-AAGTTCCCTGCCATCAGAAG-30. The amplified
fragments were then cloned upstream of a basal promoter in the
pGL4.28-luc vector (Promega). A total of four vectors were pro-
duced: MFN2:655(C)-Luc, MFN2:665(T)-Luc, MFN2:1928(C)-Luc,
andMFN2:1928(T)-Luc. 2 mg of aMFN2-Luc vector was transfected
along with 0.5 mg CMV-b-gal-expressing plasmid into 5 3 105
K562 cells. 24 hr after transfection, lysates were measured for016
Figure 1. Genome-wide View of Platelet
eGenes
The y axis shows maximum log10
p values of eQTLs for 612 platelet eGenes.
The x axis corresponds to ordering along
22 autosomal chromosomes. The top 40
eGene symbols have been added to the
plot. Color coding of points and back-
grounds is used to help separate chromo-
somes visually.luciferase activity on a FLUOstar OPTIMA plate reader (BMG
Labtech) and b-gal activity with a beta-Galactosidase Assay Kit
(ThermoFisher). Results are expressed as a ratio of luciferase activ-
ity normalized to b-gal activity.
Statistical Analyses
Statistical analyses were conducted with R statistical software. To
evaluate the significance of differences in the distribution of
eQTL peaks between platelets and GTEx tissues, we performed
the Grubbs single-outlier test on the proportion of eQTL peaks
mapping into the gene body by using the ‘‘grubbs.test’’ function
from the ‘‘outliers’’ R package. We used Spearman’s rank correla-
tion to assess significance between the exon 2b inclusion rate
and rs1474868 allele dosage. We used Mann-Whitney tests as im-
plemented in the ‘‘wilcox.test’’ R function to evaluate significance
of differential luciferase activity. We used the LDlink online tool
to assess linkage disequilibrium. To best represent our study
cohort, we restricted linkage-disequilibrium calculations to the
1000 Genomes populations ASW (Americans of African ancestry
in southwest USA) and CEU (Utah residents with ancestry from
northern and western Europe from the CEPH collection). We
used a multiple-linear-regression framework implemented in the
R ‘‘aov’’ function to evaluate the significance of the association
among platelet count, the rs3766744 genotype, and MFN2
expression levels in the PRAX1 study data. For the rs3766744
variant, the model explained platelet count by using rs3766744
allele dosage after accounting for the marginally significant cova-
riates body mass index, gender, and self-identified ethnicity.
For MFN2 expression levels, the model explained platelet count
by using MFN2 expression levels after accounting for the same
covariates.Results
Two-Pass cis eQTL Mapping Identifies 612 Platelet
eGenes
The PRAX1 study profiled mRNA expression levels from
platelets and genotypes of 154 healthy human subjects
on array platforms.26 To decrease computational burden
while increasing genetic resolution, we applied a two-
pass strategy for mapping the landscape of human platelet
cis eQTLs (see Material and Methods). 5,695 autosomal
commonly expressed platelet genes, as defined in Simon
et al.,28 were used in the analysis. We identified a total of
44,940 significant eQTLs (p < 1e6) implicated in expres-
sion association with 612 unique genes, termed plateletThe AmeGenes. The rates of the number of eGenes per gene tested
and significant eQTLs per eGene were comparable to those
of other studies with similar sample sizes (Figure S2).
Figure 1 presents the distribution of the strongest associa-
tion p values for each eGene across the 22 autosomal chro-
mosomes tested. To assess how many eQTLs contribute to
the association signal of an eGene, we performed condi-
tional eQTL analysis. 560 (92%) eGenes did not contain
any significant eQTLs after we accounted for the eQTL
peak, indicating that most platelet eGenes are regulated
by a single genetic signal. The MatrixEQTL output for all
612 platelet eGenes is contained in Table S1. These results
can be interactively queried on our Plateletomics website
(see Web Resources).
ASE Analysis Confirms Global eQTL Results In Silico
An eQTL measures the association between genotype and
gene expression across samples, whereas ASE measures
allelic imbalance at a heterozygous site within a single
sample.45 Concordance between the allelic directionality
of allelic imbalance and an eQTL can be interpreted as
an independent validation of the eQTL.46 Figure S3
contains a detailed schematic describing the relationship
between eQTLs and ASE. Therefore, we performed
allelic-imbalance analysis (see Material and Methods). In
brief, to validate eGenes by using allelic imbalance, we
generated read pileups at heterozygous coding sites of
all platelet eGenes in all ten RNA-seq samples from the
PRAX1 study. A total of 116 (19%) eGenes contained at
least one qualifying pileup site with marginal eQTL effect
(p < 1e4) in one or more of the ten samples and pro-
vided the opportunity to confirm eQTL effects via
allelic-imbalance analysis. We classified all pileup sites of
these 116 eGenes according to the allelic directionality
of the linked eQTL. Reference and alternatives sites were
defined as pileup sites where the linked eQTL showed
higher expression of the reference and alternative allele,
respectively.
Figure 2A presents the counts of reference and alterna-
tive alleles observed at 358 pileup sites corresponding to
116 unique eGenes (Table S2). 266 (75%) alternative and
reference sites fell above and below the diagonal line,
respectively. The allelic imbalances are in concor-
dance with the allelic directionality of the eQTLs anderican Journal of Human Genetics 98, 883–897, May 5, 2016 887
Figure 2. Confirmation of eQTLs via ASE
(A) Points represent allele counts at 358 heterozygous coding sites
with amarginal eQTL effect (p< 1e4). Reference and alternatives
sites are colored in blue and red, respectively. The black diagonal
line indicates the null-hypothesis distribution of equal counts of
the reference and alternative alleles.
(B) Manhattan plot of eQTL landscape for eGene CXCL5. The
y and x axes correspond to association p values and genomic coor-
dinates, respectively. Blue and black points show imputed
and genotyped variants, respectively. The red point shows refer-
ence site rs425535, and the green point shows lead eQTL
rs201022772. Transcription start and end sites of CXCL5 are indi-
cated by green and red vertical lines, respectively. Gray rectangles
below the plot represent CXCL5 exons.
(C) Boxplot shows significant association between CXCL5 expres-
sion levels and rs425535 allele dosage (p< 10e12,multiple linear
regression).The x axis shows the alternative allele count. Numbers
in parentheses indicate the number of samples within each group.
The y axis represents expression levels of CXCL5 corrected for co-
variates. The box represents the interquartile range, the horizontal
line in the box indicates the median, and the whiskers represent
1.53 the interquartile range.
(D) Reference and alternative allele counts at rs425535 for six het-
erozygous RNA-seq samples from the PRAX1 study are shown on
the x and y axis, respectively.demonstrate the agreement between eQTLs and ASE (p <
1e19, Fisher’s exact test).
Figures 2B–2D depict CXCL5 (MIM: 600324), a represen-
tative eGene. CXCL5 was chosen because it shows signifi-
cant allelic imbalance in concordance with the allelic
directionality of the eQTL (p < 2.2e16, binomial test;
see Material and Methods for additional details). CXCL5
is a neutrophil-recruiting chemokine that is secreted by
platelets. Platelet-released CXCL5 participates in the path-
ogenesis of coronary artery disease and tumor metasta-
ses.47,48 The Manhattan plot in Figure 2B shows the
eQTL landscape of CXCL5. The reference site rs425535
(red point) is in the second exon of the gene and was in888 The American Journal of Human Genetics 98, 883–897, May 5, 2linkage disequilibrium with the lead eQTL rs201022772
(green point). High CXCL5 expression levels were associ-
ated with the reference allele of variant rs425535 (p <
10e12, multiple linear regression; Figure 2C). Corre-
spondingly, ASE analysis at rs425535 revealed a higher
proportion of the reference allele within all six heterozy-
gous samples (Figure 2D). We interpret these results as
in silico ASE validation of the eGene CXCL5.
Platelets Share eGenes with Other Tissues
To compare our platelet eQTLs to those identified in other
tissues, we reanalyzed GTEx eQTL data23 from 20 different
tissues isolated from human cadavers. To improve compa-
rability, we applied our definition of eGenes to the GTEx
data (Material and Methods; Table S3). 525 platelet
eGenes (86%) were also identified as eGenes in at least
one of the GTEx tissues analyzed (p < 2.2e16, binomial
test), additionally validating our eQTL results. To investi-
gate eGenes at a higher resolution, we compared
variant-gene associations of our platelet eQTLs to corre-
sponding variant-gene associations tested in the GTEx
data. We observed a 75% median concordance rate for
the sign of the effect between platelet eQTLs and GTEx
tissues, indicating that eGenes commonly share the allelic
directionality of their eQTLs (median p value across tis-
sues < 1e6, Fisher’s exact test; Figure S4). 33 platelet
eGenes were classified as eGenes in all 20 GTEx tissues
and were therefore considered global eGenes. To evaluate
overlap between platelet eGenes and each GTEx tissue
separately, we calculated Jaccard similarity. The GTEx tis-
sue ‘‘whole blood’’ shared the highest fraction of eGenes
with platelets (258 common eGenes). A total of 110
platelet eGenes were identified as platelet specific because
they were observed exclusively in platelets, exempting the
GTEx tissue ‘‘whole blood,’’ of which platelets are a
component (Figure 3A).
Platelet eQTL Peaks Tend to Localize in the Gene Body
To examine eGenes at a more granular level, we defined
eQTL peaks as the genomic location of the variant(s)
with the strongest association with a given eGene. We
identified all eQTL peaks in platelets and GTEx tissues
independently. When we compared eQTL peaks to the
eGene’s transcription start and stop sites across tissues,
platelets had an unusually large proportion of eQTL peaks
(54%)mapping to the gene body (p< 1e8, Grubbs single-
outlier test; Figure 3B). This finding suggests that anucleate
platelets might be subjected to an expression-regulation ar-
chitecture that is distinct from that of other tissues with
active transcription.
When both GTEx data and platelets have eQTLs for the
same eGene, a variety of patterns can emerge. We high-
light two exemplary eGenes, such as FHL3 (MIM:
608898), known to play a role in platelet biology. Platelets
require Munc13-4 for granule fusion and release,49 and
mutations in FHL3 cause defective secretion and familial
hemophagocytic lymphohistocytosis.50 Figure 3C depicts016
Figure 3. Comparison of Platelet eQTLs
with GTEx
(A) Heatmap columns and rows represent
platelet eGenes and GTEx tissues, respec-
tively. The color of the heatmap represents
the classification of each platelet eGene as
either an eGene (green) or not an eGene
(purple) in each of the GTEx tissues. Gray
colors indicate genes not tested for eQTLs
in the given tissue. In the bar above the
heatmap, green and red represent global
and platelet-specific eGenes, respectively,
and gray indicates platelet eGenes co-
occurring in one or more GTEx tissues.
The adjacent barplot shows Jaccard simi-
larity comparing the overlap between
platelet eGenes and GTEx tissues.
(B) The relative distribution of eQTL peaks
across the gene body for all tissues. The
box represents the interquartile range,
the horizontal line in the box indicates
the median, and the whiskers represent
1.53 the interquartile range.
(C and D) The location of eQTL peaks
for eGenes FHL3 and GRB14. The y and
x axes correspond to the log10 p value
of eQTL peaks and genomic location,
respectively. Green and red vertical lines
illustrate the transcription start and stop
sites, respectively, for each gene.the eQTL peaks for the eGene FHL3 across studies. A clus-
ter of eQTL peaks mapped just downstream of the tran-
scription stop site (red vertical line) in multiple tissues,
and eQTL peaks fell even further downstream in ‘‘heart-
atrial appendage’’ and ‘‘breast-mammary tissue.’’ How-
ever, the eQTL peaks for platelets (red asterisk) and the
GTEx tissue ‘‘whole blood’’ (purple square) overlapped
each other and mapped, distinct from the other GTEx
tissues, into the gene body. This observation suggests
that the molecular regulation underlying FHL3 expression
might be similar in platelets and blood and different from
that in other tissues.
Figure 3D depicts the eQTL peaks for an additional exem-
plary platelet eGeneGRB14 (MIM: 601524), which encodes
growth factor receptor-bound protein 14. This protein is an
adaptor that regulates receptor tyrosine kinase signaling,
platelet signaling, and integrin activation.51 The platelet
eQTL peak localized to the gene body, whereas in the
GTEx tissue ‘‘esophagusmuscularis,’’ the eQTL peak fell up-
stream of the gene.The American Journal of HumaOverlap between Platelet eQTL
Peaks and MI Variants in MFN2
To assess our eQTL findings in the
context of CVD GWAS results, we sys-
tematically compared our eQTL find-
ings to data from the Genotype and
Phenotype Integrator.25 A total of
3,850 unique variants were previ-
ously reported to be associated with
the risk of CVD in various studies ata p value threshold of 1e4. After restricting this set of var-
iants to those implicated in our eQTL analysis at amarginal
p value cutoff of 1e4, we identified 40 associations, where
platelet eQTLs were previously linked to CVD by GWASs
(Table 1). The genetic variant rs1474868 was identified as
the variant most strongly associated with platelet MFN2
expression levels (p < 1e47, multiple linear regression;
Figure 4) and was the strongest eQTL of all GWAS CVD-
linked variants. The variant rs1474868 was previously
associated with MI in the STAMPEED: Cardiovascular
Health Study (phs000226) and localized to the second
intron of the first transcript isoform (GenBank:
NM_014874) of MFN2. Using our ASE approach, we vali-
dated the eQTL association between rs1474868 and
MFN2 expression levels (Figure S5).
Platelet RNA-Seq Data Reveal Unannotated Exon 2b
in MFN2
MFN2 encodes mitofusin-2, a critical membrane protein
involved in mitochondrial fusion, and normal plateletn Genetics 98, 883–897, May 5, 2016 889
Table 1. Platelet eQTLs Overlap Variants Implicated in CVD GWASs
SNP Gene Gene MIM No. eQTL p Value Trait Study ID
rs1474868 MFN2 608507 8.94e47 myocardial infarction 2873
rs780633 RSU1 179555 2.71e42 stroke 2887
rs2701268 PDK1 602524 1.66e21 stroke 2886
rs7349405 CLHC1 (C2orf63) NA 7.72e20 hypertension 3041
rs2285515 FXYD5 606669 1.96e19 Behcet syndrome 2888
rs6869332 ELOVL7 614451 1.06e14 stroke 2887
rs6738196 PDK1 602524 1.37e12 stroke 2886
rs3769321 PDK1 602524 1.00e11 stroke 2886
rs514659 ABO 110300 2.85e10 cardiovascular diseases NA
rs10863938 LPGAT1 610473 2.26e9 stroke 2886
rs10499859 CD36 173510 5.12e9 hypertension NA
rs712665 REEP5 125265 6.46e9 stroke 2886
rs9962325 NAPG 603216 6.47e9 carotid stenosis 966
rs411356 REEP5 125265 8.28e9 stroke 2886
rs505922 ABO 110300 1.60e8 venous thrombosis NA
rs505922 ABO 110300 1.60e8 venous thromboembolism NA
rs4756196 CD44 107269 8.27e8 stroke 2887
rs12242391 TSPAN15 613140 3.21e7 stroke 2887
rs4937126 ST3GAL4 104240 3.30e7 coronary artery disease NA
rs2522447 PAPSS1 603262 7.90e7 coronary disease 3056
rs102275 FADS2 606149 1.69e6 hypertrophy, left ventricular 3052
rs6935954 HIST1H2BD 602799 2.44e6 stroke 2887
rs102275 FADS1 606148 2.77e6 hypertrophy, left ventricular 3052
rs2980996 PIGN 606097 2.81e6 heart failure 2884
rs174576 FADS1 606148 3.54e6 hypertrophy, left ventricular 3052
rs174576 FADS2 606149 3.68e6 hypertrophy, left ventricular 3052
rs973126 PAPSS1 603262 4.38e6 coronary disease 3056
rs973126 PAPSS1 603262 4.38e6 coronary disease 3055
rs9258966 HLA-H NA 4.42e6 Behcet syndrome 2888
rs3094654 HLA-H NA 4.42e6 Behcet syndrome 2888
rs2256919 ZFP57 612192 5.73e6 Behcet syndrome 2888
rs6594646 REEP5 125265 6.88e6 stroke 2886
rs663354 PIGN 606097 7.78e6 heart failure 2884
rs2431512 REEP5 125265 8.53e6 stroke 2886
rs12719151 REEP5 125265 1.15e5 stroke 2886
rs4694656 CXCL5 600324 2.18e5 heart failure 2885
rs13325747 RPN1 180470 2.65e5 heart failure 2885
rs4601174 CD164 603356 2.95e5 heart failure 2885
rs2071653 ZFP57 612192 3.91e5 Behcet syndrome 2888
rs1339965 SMYD3 608783 4.58e5 heart failure 2885
This table contains marginal platelet eQTLs (p< 1e4) that have been previously associated with CVD. The ‘‘Study ID’’ column contains the study cohort in which
the association between SNP and trait was detected. NA stands for ‘‘not available.’’
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Figure 4. MFN2 eQTL Manhattan Plot
The y and x axes correspond to association p values and genomic
coordinates, respectively. Blue and black points show imputed and
genotyped variants, respectively. Four variants (points fall on top
of each other) were strongly associated with MFN2 expression
levels (p < 1e45, multiple linear regression), and the red point
highlights the eQTL peak rs1474868 (genotyped). Transcription
start and stop sites are indicated by green and red vertical lines,
respectively.
(Inset) The association between rs1474868 allele dosage andMFN2
expression levels (significant at p < 1e47, multiple linear regres-
sion). The y and x axes indicate the corrected MFN2 expression
levels and rs1474868 genotype, respectively. Numbers below the
genotype labels indicate the number of samples within each
group. The box represents the interquartile range, the horizontal
line in the box indicates the median, and the whiskers represent
1.53 the interquartile range.number and function depend on mitochondrial func-
tion.52 Because the presence of a number of transcribed in-
tronic regions was previously noted in human platelets,53
we hypothesized that platelets might contain uncharacter-
ized transcripts that coincide with our platelet eQTL sig-
nals. Motivated by this hypothesis, we analyzed human
platelet RNA-seq data from multiple groups29,40–42 to
examine the transcriptional landscape of platelet MFN2.
A large number of reads mapped to MFN2 intron 2, over-
lapping the eQTL peak rs1474868 (Figure 5A and
Figure S6). RNA-seq data from mouse platelets40 lacked
reads mapping to this region in the MFN2 homolog
(Figure S7). We hypothesized that this RNA-seq mapping
represents the existence of an unannotated human-
platelet-expressed exon, which we call ‘‘exon 2b.’’ We
used RT-PCR of RNA from human platelets to confirm
the presence of exon 2b in the MFN2 transcript
(Figure S8), and sequencing of the RT-PCR products re-
vealed a precise exon 2b location (chr1: 12,043,880–
12,044,352, hg19). To test whether exon 2b is present in
other tissues, we performed in silico cross-tissue analysis.
We were unable to identify comparable expression levelsThe Amof exon 2b in mRNA-seq data from any of the 69 Epige-
nome Roadmap sample types queried, suggesting that
exon 2b is preferentially expressed in human platelets
(Figure 5B).
Exon 2b Is an Alternative Start Site of MFN2
To infer how exon 2b fits into the splicing pattern ofMFN2,
we examined RNA-seq junction reads from a total of 45
RNA-seq samples of human platelets. We were unable to
detect any reads connecting exon 2b to any upstream
exon, suggesting that exon 2b is an alternative 50 start
site. Using the 50 RACE assay, we verified the presence of
two separate platelet MFN2 isoforms starting at either
exon 2b or exon 1 (Figure S9). Next, we estimated the
relative abundance of the MFN2 isoform containing exon
2b. Using junction reads connecting the 50 border of
exon 3 to any upstream exon can unambiguously distin-
guish between MFN2 isoforms. A median of 86% of junc-
tion reads mapped from the 30 border of exon 2b to the
50 border of exon 3, suggesting that exon 2b is included
in the pre-dominant platelet MFN2 isoform (Figure 5C).
Moreover, the relative abundance of this MFN2 isoform
was significantly associated with the rs1474868 genotype
(p < 1e6, Spearman’s rank correlation; Figure 5D).
The Variant rs3766744 Alters Transcriptional Activity
eQTLs have been shown to regulate gene expression by
altering transcription factor binding sites;54 therefore, we
integrated ENCODE transcription factor ChIP-seq data
from K562 myeloid leukemia cells to identify the most
likely causal eQTL for MFN2. Three noncoding variants
(rs4846082, rs4845891, and rs3766744) were in near per-
fect linkage disequilibrium with rs1474868 and also
strongly associated with MFN2 expression levels (all three
p < 1e45, multiple linear regression). Among this set of
variants, we observed an overlap of 32 transcription factor
ChIP-seq peaks with rs3766744 (Figure 6A), suggesting a
potential mechanism for this variant.
To evaluate the effect of genotype on transcriptional ac-
tivity, we generated vectors containing short (S: 655 bp) or
long (L: 1,928 bp) DNA fragments flanking rs3766744
upstream of a luciferase reporter gene. Clones of the
rs37466744 C and T alleles were generated. Transfection
of these reporter constructs into K562 cells resulted in a sig-
nificant difference of luciferase activity between the C and
T alleles for both S and L clones (Figure 6B). These results
are in concordance with the allelic directionality of our
MFN2 eQTL and ASE findings and support rs3766744 as
the causal regulatory variant.
MFN2 Expression Is Associated with Platelet Count
After identifying rs3766744 as the probable causal regula-
tory variant that controls MFN2 expression levels, we
investigated the association among rs3766744 allele
dosage, MFN2 expression, and platelet count by using
our data from the PRAX1 study. Platelet count was signifi-
cantly associated with rs3766744 allele dosage (p < 1e4,erican Journal of Human Genetics 98, 883–897, May 5, 2016 891
Figure 5. Novel Exon in MFN2
(A) Read coverage across MFN2 for a single representative human
platelet RNA-seq sample (SRA: SRR957099). Blue bars represent
RNA-seq read coverage. Gray rectangles indicate exons of MFN2
transcripts uc001atn.4 and uc009vni.3. The black arrow high-
lights a pile of reads mapping to an intronic region overlapping
rs1474868 (red vertical line).
(B) Average exon 2b expression levels across 69 Epigenome
Roadmap mRNA-seq sample types (gray bars) and the Londin
et al.29 human platelet RNA-seq data (purple bar). The y axis indi-
cates the exon 2b expression level in relation to that of the most
highly expressed MFN2 exon.
(C) Estimated relative abundances of MFN2 isoforms in platelets.
The schematic below the plot depicts annotated exons 1–3 and
novel platelet exon 2b of MFN2. Red, green, and blue lines indi-
cate mapping of informative RNA-seq junction reads for the
isoform containing the novel exon 2b and annotated MFN2
isoforms uc001atn.4 and uc009vnl.3, respectively. The boxplot
shows the estimated relative abundance for each of these isoforms
across human platelet RNA-seq samples. The box represents the
interquartile range, the horizontal line in the box indicates the
median, and the whiskers represent 1.53 the interquartile range.
(D) Estimated relative abundance of theMFN2 isoform containing
exon 2b by the inferred rs1474868 genotype. The relative abun-
dance of this isoform was significantly associated with the
rs1474868 genotype (p < 1e6, Spearman’s rank correlation).
The box represents the interquartile range, the horizontal line in
the box indicates the median, and the whiskers represent 1.53
the interquartile range.multiple linear regression; Figure 7A) andMFN2 expression
levels (p < 1e3, multiple linear regression; Figure 7B).
Moreover, after conditioning on MFN2 expression levels,
the association between rs3766744 and platelet count dis-
appeared; however, the association between rs3766744892 The American Journal of Human Genetics 98, 883–897, May 5, 2and MFN2 expression levels remained significant after
platelet count was accounted for. Together, these condi-
tional association analyses support a causal model where
MFN2 expression levels mediate the association between
rs3766744 and platelet count (Figure 7C).Discussion
CVD GWASs have been successful at identifying loci asso-
ciated with disease risk,55,56 but linking these variants with
gene function in relevant tissues has been a challenge.16
Platelets are a critical tissue for this analysis because they
are an important contributor to clinical CVD phenotypes
and are the target of pharmacologic interventions. In this
study, we used platelet transcriptomics and eQTL analyses
to uncover platelet-specific gene regulation that corre-
sponds to a CVDGWAS signal inMFN2. This study demon-
strates the power of combining tissue-specific eQTL and
RNA-seq data with large-scale genomic databases to gain
greater insight into the molecular mechanisms underlying
GWAS signals.Validation of Platelet eQTLs
To corroborate the expression associations revealed in our
study, we pursued both overlap with external data and ASE
analysis of our own genome-wide genotype and transcrip-
tome data. We utilized imputation to provide a more gran-
ular view of the eQTL landscape, enhancing our ability to
make direct comparisons tomarkers in other studies.57 Sec-
ond, the imputation approach also determined a more
fine-scale substrate for overlap with ChIP-seq analyses. A
third benefit of imputation is the improved ability to
perform ASE analysis by extending the set of coding vari-
ants linked to eQTLs.
Wevalidated eGenesbyanalyzingallelic imbalance athet-
erozygous coding sites that had sufficient read coverage and
were also in strong linkage disequilibrium with our eQTL
peaks.35Wewere able to examine 19% of all platelet eGenes
despite the following limitations: (1) only a subset (6.4%) of
our cohort was profiled by RNA-seq technology, (2) only a
subset (79%) of eGenes contained at least one heterozygous
coding site, and (3) only a subset (13%) of pileup sites con-
tained sufficient read coverage for analysis. Globally, the
trends indicated a significant concordance between the
allelic directionality of eQTLs andRNA-seq allelic-imbalance
events inplatelet eGenes.Our data suggest that RNA-seq of a
subset of subjects for ASE analysis is a useful approach for
validating eQTLs developed through microarray studies of
geneexpression.This approachcouldbeadoptedonexisting
data where microarray studies have determined eQTLs but
where subsampleRNA-seqcould refinecandidates for valida-
tion and further functional studies.Characterization of Platelet eQTLs
We integrated and analyzed our primary dataset with GTEx
findings to both validate our results and investigate tissue016
Figure 6. Differential Regulation of
MFN2 Expression by Single-Nucleotide
Variant
(A) ENCODE K526 ChIP-seq transcription
factor binding peaks clustered near
rs1474868. Red vertical lines indicate
the location of genetic variants strongly
associated with MFN2 expression levels.
rs3766744 overlapped a number of tran-
scription factor binding sites. The names of
transcription factors are ordered from bot-
tom to top. Exon 2b is displayed as a cyan
rectangle. The S and L clones are shown as
purple and gray rectangles, respectively.
(B) Differential luciferase activity for the
C and T alleles of rs3766744 in the S and
L clones. The luciferase levels were higher
for the C allele than for the T allele (both
p < 0.05, Mann-Whitney test). Error bars
correspond to SE.specificity of platelet eQTLs. We acknowledge the diffi-
culties of making comparisons across data produced by
different groups on different platforms. Our study has
the advantage of highly purified cells obtained from living,
healthy subjects. Samples from the PRAX1 study were sub-
jected to a uniform and immediate specimen processing,
including RNA isolation and extraction within 1 hr of
phlebotomy. Our results indicate that platelets have tis-
sue-specific eQTLs distinct from those identified by
GTEx, highlighting the need to extend GTEx studies to
additional tissues and biological contexts.
Compared to other cell types, platelet eQTL peaks show
an unusually high representation in the gene body
(Figure 3D). This finding is intriguing because platelets
are anucleate cells free of genomic DNA. RNA messages
are inherited from parent megakaryocytes, potentially
decreasing the relative impact of transcriptional regulatory
regions and increasing the significance of post-transcrip-
tional regulation. This stands in sharp contrast to the
other cell types profiled in GTEx, where the transcriptome
reflects a balance between transcription and RNA degrada-
tion. Further analyses of other anucleate cells, such as
erythrocytes, might yield additional insights.
Functional Genomics of Platelet MFN2
Our genome-wide eQTL analysis revealed that rs1474868
marks the eQTL peak of MFN2. The function of MFN2 in
platelets and megakaryocytes has not been studied, and
our work demonstrates the presence of MFN2 transcripts
(Figure 5) and protein (Figure S10) in human platelets.
MFN2 is a gene previously reported to function in mito-
chondrial structure and function.58,59 Follow-up analyses
using RNA-seq data determined that MFN2 has an un-
annotated alternate first exon, exon 2b, which overlaps
rs1474868. Inclusion of exon 2b is predicted to add 34
amino acids to the N terminus of the MFN2 RefSeq
coding sequence; we term this extended protein pMFN2
(Figure S11). The anti-MFN2 antibody used to detect
MFN2 does not distinguish between MFN2 and pMFN2.
We raised a polyclonal antibody against amino acidThe Amsequence unique to the predicted pMFN2, but unfortu-
nately it reacted non-specifically with numerous polypep-
tides and was not useful (data not shown). However,
because 86% of MFN2 transcripts contained exon 2b
(Figure 5C), we presume the major form observed by west-
ern blotting is pMFN2 (Figure S10), but until additional re-
agents are developed or mass spectrometry of purified
pMFN2 is performed, we cannot be certain.
In addition, in silico cross-tissue analysis suggests that
this alternate start site is platelet specific. A previous study
by Nuernberg et al.60 identified a novel 50 start site in RNA-
seq data from megakaryocytes in the gene DNM3, and we
also found this start site in our platelet RNA-seq data
(data not shown). Our discovery of an unannotated 50
alternative start site in platelet MFN2, along with similar
observations of platelet-specific exons by others,61 suggests
that unannotated lineage-specific alternative 50 start sites
might be common in platelets and platelet progenitor
cells. This is an exciting area for further studies.
MFN2 and Platelet Count
We observed a significant association between platelet
count and rs3766744, which is in linkage disequilibrium
with rs1474868 (Figure 7). Conditional association anal-
ysis suggests that this relationship is mediated through dif-
ferential MFN2 expression driven by allele dosage. Variant
rs3766744 is also in linkage disequilibriumwith rs2336384
(R2 ¼ 0.49, LDlink), which has previously been linked to
platelet count.7 We were able to verify this association in
our data from the PRAX1 study (p < 0.05, multiple linear
regression). However, in the analysis of these data, the as-
sociation between rs3766744 and platelet count was stron-
ger than the association between rs1474868 and platelet
count, suggesting that the platelet-count association
might be driven by rs3766744.
Our working hypothesis is that rs3766744 regulates
exon 2b utilization by altering transcriptional enhancer ac-
tivity, which in turn leads to increased MFN2 expression.
Numerous transcription factors were shown to bind to
the sequence potentially altered by rs3766744 in K562erican Journal of Human Genetics 98, 883–897, May 5, 2016 893
Figure 7. Associations with Platelet Count in the PRAX1 Study
Dataset
(A) The association between rs3766744 and platelet count (p <
1e4, multiple linear regression). The box represents the inter-
quartile range, the horizontal line in the box indicates themedian,
and the whiskers represent 1.53 the interquartile range.
(B) The association between platelet count and MFN2 expression
levels (p < 1e3, multiple linear regression).
(C) Our proposed model. The variant rs3766744 controls MFN2
expression levels, which in turn affect platelet count.cells (Figure 6A). Particularly interesting candidates are
GATA2, TAL1, and ETS1, which are known to regulate meg-
akaryocytopoiesis and expression of many platelet-specific
genes. We further hypothesize that variation in MFN2
expression alters platelet production given that low Mfn2
expression has been linked to mitochondrial damage in
mice,62 and mitochondrial number and function are crit-
ical for platelet production by megakaryocytes. Never-
theless, addressing these testable hypotheses will require
much more work and the development of new reagents.
MFN2 and Human Disease
Normal platelet function and lifespan depend on healthy
mitochondria as a critical energy source during their
10 day period in circulating blood. There are numerous
clinical conditions wherein the platelet count is signifi-
cantly reduced in association with dysfunctional mito-
chondria, including inherited and acquired diseases
inducing mitochondrial dysfunction.52,63–67
Variation in MFN2 has been linked to Charcot-Marie-
Tooth disease (CMT) type 2A2 (MIM: 609260) and heredi-
tary motor and sensory neuropathy VIA (MIM: 601152).
MFN2 mutations are associated with the disease subtype
CMT2A, where diverse coding mutations inMFN2 account
for up to 20% of the CMT2A subtype and about 4% of
CMT disease overall.68 The CMT2A-linked mutations in
MFN2 comprise a diverse collection of variants, including
stop-gain and non-synonymous pathogenic changes.
Pathogenicity has been connected to more variants in
the N terminus of the protein, but variations across the
protein have been linked to the disease.69
Not only does MFN2 play a role in Mendelian disease,
but there is also evidence thatMFN2might have a function894 The American Journal of Human Genetics 98, 883–897, May 5, 2in later-onset complex diseases such as CVD. Common
variants in MFN2 have been linked to platelet count7 and
the risk of MI25 and hypertension.70 In addition, muta-
tions in MFN2 have also been linked to early-onset
stroke.71 Furthermore, it is generally believed that an
elevated platelet count is a risk factor for ischemic cardio-
vascular complications, although this has not been rigor-
ously studied in a prospective fashion. Subjects with very
high platelet counts due to acquired, clonal myeloprolifer-
ative diseases are at an increased risk of MI and stroke, and
standard management most often includes anti-platelet
therapies.72Sharing of Results
Wehavemadeour results availablebyextendingour interac-
tive Plateletomics website (see Web Resources). We added a
platelet-eQTL browser function, allowing users to quickly
and easily query our platelet-eQTL results. This eGene anal-
ysis can be particularly useful in cases where wet-bench ex-
periments might give conflicting results if the investigator
does not consider the genotype of the donors used.Conclusion
Our study of platelet eQTLs identified 612 platelet eGenes.
Among these, MFN2 harbored the strongest eQTL that
corresponded to a previously reported CVD GWAS variant.
Integrative analysis demonstrated that the MFN2 eQTL
identified an unannotated alternate platelet-specific 50
start site driving MFN2 expression. Moreover, MFN2 levels
were strongly associated with platelet count, a known risk
factor for CVD. Our results reinforce using multi-omic data
integration of relevant primary tissues to functionalize
GWAS signals.Supplemental Data
Supplemental Data include 11 figures and 4 tables and can be
found with this article online at http://dx.doi.org/10.1016/j.
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